Valeant (VRX) Shares Rise Following FY12 Outlook
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Income from continuing operations attributable to Valeant: 0.42
Today's EPS Names:
EDXC, BICX, FBPI, More
Financial Fact:
Income from continuing operations attributable to Valeant: 0.42
Today's EPS Names:
EDXC, BICX, FBPI, More
Join SI Premium – FREE
Shares of Valeant Pharma (NYSE: VRX) have just turned positive following an 8-K filing which offers some insight into FY12 results.
Valeant expecting FY12 sales of $3.1-$3.4 billion and cash EPS of $3.95-$4.20. The company expects adjusted cash flow from operations to be greater than $1.2 billion.
Valeant expecting FY12 sales of $3.1-$3.4 billion and cash EPS of $3.95-$4.20. The company expects adjusted cash flow from operations to be greater than $1.2 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
- Robo.ai completes acquisitions, plans interim report for Aug. 24
- Target (TGT) Tops Q2 EPS by $1.78, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Guidance, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
